As a negative regulator of JAK2, inactivating mutations in the SH2B3 gene lead to weakened negative regulation of the JAK2/STAT signaling pathway by the SH2B3 protein, thereby causing continuous activation of this pathway and inducing the development of MPN. This evidence concerns the gene SH2B3 and myeloproliferative disorder.